Publication:
Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics

2
0

Issued Date

2011

Resource Type

Review

File Type

application/pdf

ISSN

20415990

DOI

10.4155/tde.11.60

Other identifier(s)

2-s2.0-79961177838

Rights Holder(s)

Scopus

Bibliographic Citation

Therapeutic Delivery. Vol 2, No.7 (2011), p.873-889

Suggested Citation

Chittasupho C., Siahaan T.J., Vines C.M., Berkland C. Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. Therapeutic Delivery. Vol 2, No.7 (2011), p.873-889. doi:10.4155/tde.11.60 Retrieved from: https://hdl.handle.net/20.500.14740/7302

Title

Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics

Author(s)

Chittasupho C.
 Siahaan T.J.
 Vines C.M.
 Berkland C.

Abstract

Proteins participating in immunological signaling have emerged as important targets for controlling the immune response. A multitude of receptor-ligand pairs that regulate signaling pathways of the immune response have been identified. In the complex milieu of immune signaling, therapeutic agents targeting mediators of cellular signaling often either activate an inflammatory immune response or induce tolerance. This review is primarily focused on therapeutics that inhibit the inflammatory immune response by targeting membrane-bound proteins regulating costimulation or mediating immune-cell adhesion. Many of these signals participate in larger, organized structures such as the immunological synapse. Receptor clustering and arrangement into organized structures is also reviewed and emerging trends implicating a potential role for multivalent therapeutics is posited. © 2011 Future Science Ltd.

Subject(s)

Abatacept
 Adalimumab
 Autoantibody
 B7 antigen
 Belatacept
 CD28 antigen
 Cholinergic receptor
 Corticosteroid derivative
 Cytokine
 Cytotoxic agent
 Cytotoxic T lymphocyte antigen 4
 Dacetuzumab
 Efalizumab
 Etanercept
 Galiximab
 Immunoglobulin
 Infliximab
 Intercellular adhesion molecule 1
 Intercellular adhesion molecule 1 antibody
 Ipilimumab
 Lymphocyte function associated antigen 1
 Major histocompatibility antigen class 2
 Membrane protein
 Methotrexate
 Natalizumab
 Programmed death 1 receptor
 Rituximab
 Thyrotropin receptor
 Ticilimumab
 Unindexed drug
 Antigen presenting cell
 Autoimmune disease
 Autoimmunity
 B cell lymphoma
 Brain infection
 Brain ischemia
 Cell adhesion
 Cellular immunity
 Chronic lymphatic leukemia
 Crohn disease
 Cytokine production
 Drug protein binding
 Drug receptor binding
 Drug targeting
 Drug withdrawal
 Human
 Immunological synapse
 Immunoregulation
 Immunostimulation
 Lymphocyte proliferation
 Melanoma
 Multiple myeloma
 Multiple sclerosis
 Nonhodgkin lymphoma
 Nonhuman
 Phase 1 clinical trial (topic)
 Phase 2 clinical trial (topic)
 Phase 3 clinical trial (topic)
 Priority journal
 Progressive multifocal leukoencephalopathy
 Psoriasis
 Review
 Rheumatoid arthritis
 Signal transduction
 T lymphocyte activation
 Animals
 Autoimmune Diseases
 Cell Adhesion
 Drug Delivery Systems
 Humans
 Immune Tolerance
 Immunological Synapses
 Inflammation
 Proteins
 Signal Transduction

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/7302

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By